Connect your AI

Sarepta Therapeutics, Inc. SRPT Price / book

Price / book at other companies

PfizerPFE

1.8×+0.2×

Regeneron PharmaceuticalsREGN

2.6×+0.2×

BioMarin PharmaceuticalsBMRN

1.7×-0.6×

InsmedINSM

50×-89.2×

Capricor TherapeuticsCAPR

6.3×+2.9×

Catalyst PharmaceuticalCPRX

3×-0.7×

Other financials

Income statement

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

Market cap$1.82B-63.1%

Enterprise value$1.56B-67.2%

P/S0.8×—

Profitability

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=1.5×

Based on the most recent quarter.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sarepta Therapeutics, Inc.'s price / book?: Sarepta Therapeutics, Inc. (SRPT) reported price / book of 1.5× in Q1 2026.
How has Sarepta Therapeutics, Inc.'s price / book changed year-over-year?: Sarepta Therapeutics, Inc.'s price / book decreased by 72.0% year-over-year, from 5.4× to 1.5×.
What is the long-term trend for Sarepta Therapeutics, Inc.'s price / book?: Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s price / book has grown at a -35.6% compound annual growth rate (CAGR), from 17.8× to 2×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.